Structural Heart Occluders

This channel includes news and new technology innovations about structural heart occluders. These include information of surgical repair and transcatheter closure of PFO, VSD, ASD and LAA. Devices include the Amplatzer and the Gore Helex

Surgeons Use Novel Occluder with a Metal-Free Frame on a Patient with ASD
May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial septal defects (ASD), or opening defect in the wall of the heart that separates the ...
Front Line Medical Technologies Expands Availability of its COBRA-OS
February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System), as ...
New ASE Guideline Outlines Acquisition of Essential Transesophaegal Echo Images in Structural Heart Prior to Intervention
January 17, 2022 – As the increasing number of structural heart interventions are assisted by real-time imaging guidance, interventional echocardiography is being recognized as a subspecialty ...
First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes
November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage (LAA) transcatheter occluder with the new generation Boston Scientific Watchman ...

News | Structural Heart Occluders

Surgeons Use Novel Occluder with a Metal-Free Frame on a Patient with ASD

May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial ...

May 05, 2022

Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System), as U.S. and Canadian hospitals continue to implement the life-saving aortic occlusion device during various surgical and emergency cases.

News | Endovascular Aortic Repair

Front Line Medical Technologies Expands Availability of its COBRA-OS

February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of ...

February 18, 2022

The ASE released new guidelines for pre-procedural structural heart echo imaging assessments. This image showing the aortic and mitral valves in life-like TrueView rendering is from a Philips Epiq CV version 9.0 system.

News | Structural Heart

New ASE Guideline Outlines Acquisition of Essential Transesophaegal Echo Images in Structural Heart Prior to Intervention

January 17, 2022 – As the increasing number of structural heart interventions are assisted by real-time imaging guidance ...

January 17, 2022

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

The Abbott Amplatzer Talisman PFO Occlusion System is designed to treat people with a patent foramen ovale (PFO). The small opening between the upper chambers of the heart can increase the risk of recurrent ischemic stroke.

News | Structural Heart Occluders

FDA Clears Abbott Amplatzer Talisman PFO Occluder

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

October 04, 2021

Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.

Feature | Left Atrial Appendage (LAA) Occluders

FDA Concerned About Higher Rates of LAA Occlusion Complications in Women

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

September 27, 2021

The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Feature | Structural Heart Occluders | By Dave Fornell, Editor

FDA Clears Abbott Portico TAVR System to Treat Aortic Valve Disease

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

September 20, 2021

News | Left Atrial Appendage (LAA) Occluders

Abbott Amplatzer Amulet LAA Occluder Offers Superior Closure Compared to Watchman

August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) ...

August 31, 2021

The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021. #LAA

News | Left Atrial Appendage (LAA) Occluders

FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation

August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage ...

August 16, 2021

CentraCare completed the first structural heart procedure in the world guided by a new 4-D hologram technology developed by EchoPixel. The augmented reality technology aims to reduce reduce procedure time, improve accuracy of the procedure, and reduce risk of complications.

Feature | Virtual and Augmented Reality

First 4D Hologram Guided Structural Heart Procedure Performed for LAA Occlusion

June 28, 2021 — CentraCare, one of the largest health systems in Minnesota, successfully completed the first structural ...

June 28, 2021

Videos | Congenital Heart

VIDEO: Advances in Congenital Heart Therapy Technologies

Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, explains some of the new ...

May 26, 2021

The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman

Feature | Left Atrial Appendage (LAA) Occluders

NCDR LAAO Registry Shows Left Atrial Appendage Occlusion Associated With Low Rate of Stroke

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

May 16, 2021

In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart. #ACC21 #ACC2021

News | Left Atrial Appendage (LAA) Occluders

Left Atrial Appendage Occlusion Reduces Stroke After Heart Surgery

May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib) ...

May 15, 2021

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Blog | Structural Heart

Creating a Structural Heart Program is an Investment in the Future of the Hospital

As a medical technology journalist, a little more than a decade ago I found myself sitting in those late afternoon ...

April 21, 2021

The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

News | Structural Heart Occluders

Bioresorbable ASD Occluder Prepares to Enter U.S. Clinical Trial

April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational ...

April 20, 2021